Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1961 1
1969 1
1970 2
1971 3
1972 2
1973 4
1974 4
1975 10
1976 6
1977 4
1978 9
1979 3
1980 7
1981 4
1982 3
1983 3
1984 4
1985 9
1986 11
1987 15
1988 6
1989 10
1990 13
1991 15
1992 24
1993 29
1994 24
1995 26
1996 52
1997 56
1998 79
1999 111
2000 140
2001 172
2002 228
2003 305
2004 315
2005 418
2006 497
2007 580
2008 663
2009 712
2010 839
2011 950
2012 1079
2013 1117
2014 1254
2015 1321
2016 1339
2017 1441
2018 1470
2019 1399
2020 1666
2021 1645
2022 1520
2023 1513
2024 1376
2025 7

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

21,603 results

Results by year

Filters applied: . Clear all
Page 1
Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial.
Erba HP, Montesinos P, Kim HJ, Patkowska E, Vrhovac R, Žák P, Wang PN, Mitov T, Hanyok J, Kamel YM, Rohrbach JEC, Liu L, Benzohra A, Lesegretain A, Cortes J, Perl AE, Sekeres MA, Dombret H, Amadori S, Wang J, Levis MJ, Schlenk RF; QuANTUM-First Study Group. Erba HP, et al. Among authors: kim hj. Lancet. 2023 May 13;401(10388):1571-1583. doi: 10.1016/S0140-6736(23)00464-6. Epub 2023 Apr 25. Lancet. 2023. PMID: 37116523 Clinical Trial.
International Delphi Consensus on the Management of AQP4-IgG+ NMOSD: Recommendations for Eculizumab, Inebilizumab, and Satralizumab.
Paul F, Marignier R, Palace J, Arrambide G, Asgari N, Bennett JL, Cree BAC, De Sèze J, Fujihara K, Kim HJ, Hornby R, Huda S, Kissani N, Kleiter I, Kuwabara S, Lana-Peixoto M, Law L, Leite MI, Pandit L, Pittock SJ, Quan C, Ramanathan S, Rotstein D, Saiz A, Sato DK, Vaknin-Dembinsky A. Paul F, et al. Among authors: kim hj. Neurol Neuroimmunol Neuroinflamm. 2023 May 31;10(4):e200124. doi: 10.1212/NXI.0000000000200124. Print 2023 Jul. Neurol Neuroimmunol Neuroinflamm. 2023. PMID: 37258412 Free PMC article.
Clinical Practice Guideline for Stroke Rehabilitation in Korea-Part 1: Rehabilitation for Motor Function (2022).
Kim DY, Ryu B, Oh BM, Kim DY, Kim DS, Kim DY, Kim DK, Kim EJ, Lee HY, Choi H, Kim HS, Lee HH, Kim HJ, Oh HM, Seok H, Park J, Park J, Park JG, Kim JM, Lee J, Shin JH, Lee JK, Oh JS, Park KD, Kim KT, Chang MC, Chun MH, Kim MW, Kang MG, Song MK, Choi M, Ko MH, Kim NY, Paik NJ, Jung SH, Yoon SY, Lim SH, Lee SJ, Yoo SD, Lee SH, Yang SN, Park SW, Lee SY, Han SJ, Lee SJ, Bok SK, Ohn SH, Im S, Pyun SB, Hyun SE, Kim SH, Ko SH, Jee S, Kwon S, Kim TW, Chang WH, Chang WK, Yoo WK, Kim YH, Yoo YJ, Kim YW, Shin YI, Park YG, Choi YH, Kim Y; KSNR Stroke CPG Writing Group. Kim DY, et al. Among authors: kim hj. Brain Neurorehabil. 2023 Jul 17;16(2):e18. doi: 10.12786/bn.2023.16.e18. eCollection 2023 Jul. Brain Neurorehabil. 2023. PMID: 37554256 Free PMC article. Review.
Authors' response.
Wang ZW, Kim HJ, Noh HK, Park HS. Wang ZW, et al. Among authors: kim hj. Am J Orthod Dentofacial Orthop. 2024 Sep;166(3):195-196. doi: 10.1016/j.ajodo.2024.06.005. Am J Orthod Dentofacial Orthop. 2024. PMID: 39277272 No abstract available.
Authors' response.
Wang ZW, Kim HJ, Noh HK, Park HS. Wang ZW, et al. Among authors: kim hj. Am J Orthod Dentofacial Orthop. 2024 Aug;166(2):100. doi: 10.1016/j.ajodo.2024.05.008. Am J Orthod Dentofacial Orthop. 2024. PMID: 39084729 No abstract available.
Serum neurofilament light chain levels at attack predict post-attack disability worsening and are mitigated by inebilizumab: analysis of four potential biomarkers in neuromyelitis optica spectrum disorder.
Aktas O, Hartung HP, Smith MA, Rees WA, Fujihara K, Paul F, Marignier R, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk DM, Cutter G, She D, Gunsior M, Cimbora D, Katz E, Cree BA; N-MOmentum study investigators. Aktas O, et al. Among authors: kim hj. J Neurol Neurosurg Psychiatry. 2023 Sep;94(9):757-768. doi: 10.1136/jnnp-2022-330412. Epub 2023 May 23. J Neurol Neurosurg Psychiatry. 2023. PMID: 37221052 Free PMC article. Clinical Trial.
21,603 results
You have reached the last available page of results. Please see the User Guide for more information.